Educational Webinar Series: The future with CAR-T cell therapy
We are back with our series of webinars which explores the way Advanced Therapeutics is driving clinicians and researchers to prepare for a new wave of therapies, revolutionising the future of paediatric health care.
Register now and hear from two esteemed leaders in the field of paediatric cancer and pioneers in CAR-T cell therapy. Chimeric Antigen Receptor (CAR) T cell therapy is the most therapeutic advancement in acute lymphoblastic leukaemia for generations and is a new form of immunotherapy approach to cancer. The CAR-T cell therapy approach represents the beginning of a new era of engineered T cells, targeting most types of cancers, changing the way we are able to treat children suffering from cancer and other diseases.
- Introduction to CAR-T cell therapy
- Clinical implementation of CAR-T cell therapy
- What’s next? CAR-T cell therapy in the future
- Q&A session – speakers, panel members and attendees
Date: 26 February 2021
Time: 2pm-3pm (AEDT)
Professor Tracey O'Brien
Prof O’Brien is the Director of the Kids Cancer Centre and Head of the Transplant and Cellular Therapies Program at Sydney Children's Hospital, Randwick. She leads a team of over 200 clinical and research staff dedicated to improving outcomes for children and adolescents with cancer. Tracey has authored more than 100 publications and has over 3000 career citations in the fields of child cancer, cellular therapies and health system research. Tracey is the current Asia, Africa and Australasian Vice Chair of the Advisory committee for the Centre for International Bone Marrow Transplant Research (CIBMTR). Tracey was the first paediatric oncologist to be appointed to the Advisory Board of Cancer Australia in 2019 and was recently appointed as the Interim Chair. In 2019, Tracey was named as one of the top 10 AFR Women of Influence winning the innovation category. In addition to her specialist medical qualifications, Tracey holds an MBA and Master of Law (Health), and is Conjoint Professor in Oncology within School of Women’s and Children’s Health, Faculty of Medicine, UNSW Sydney and is a non-executive board director for the Children’s Cancer Institute.
Dr Patrick Schlegel
Dr Schlegel is a CAR-T cancer treatment expert from Tübingen, Germany who has recently joined the Westmead Health Precinct in Sydney as part of a multi-party partnership between the University of Sydney, the Children's Medical Research Institute (CMRI) and Sydney Children's Hospitals Network (SCHN). Dr Schlegel is Professor and Head of Cellular Cancer Therapeutic and is now set to lead a new research program on CAR-T cell immunotherapy that aims to bring novel treatments to patients suffering from a wide range of malignancies. This program is part of an agreement between The University of Sydney, CMRI and biopharmaceutical company, Biosceptre (BCIQ) - who are developing anti-cancer therapies, in particular targeted therapeutics and immune-oncology products targeting most types of cancers. His major focus in research and in the clinic has always been cellular therapies. This included allogeneic stem cell transplantation and especially haploidentical stem cell transplantation.